<DOC>
	<DOCNO>NCT00479427</DOCNO>
	<brief_summary>This double-blind , two-period , placebo control cross-over Phase IIa study . This study use CB2 compound GW842166 patient osteoarthritis . The pain assessment WOMAC questionnaire use study repeat dose evaluate efficacy CB2 compound GW842166 .</brief_summary>
	<brief_title>A Study Of The Effects Of CB2 Compound Of GW842166 In Patients With Osteoarthritis</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>Male female patient , 50 80 year age . A female eligible participate study : ) nonchildbearing potential ( i.e. , physiologically incapable become pregnant , include female postmenopausal ( 1 year since last menstrual cycle ) , tubal ligation surgical sterilise ) ; , b ) childbearing potential , negative pregnancy test ( urine ) screen baseline , agree one following : Male partner sterile prior female subject 's entry study sole sexual partner female subject ; Implants levonorgestral ; Injectable progestogen ; Oral contraception ( combine progestogen ) ; Any intrauterine device ( IUD ) publish data show high expected failure rate le 1 % per year ; Barrier method use acceptable method . A diagnosis primary osteoarthritis knee least 3 month symptom duration prior screen . For patient OA knee , index knee specify . Meets American College Rheumatology ( ACR ) criteria symptomatic osteoarthritis knee define knee pain radiographic evidence osteophyte ( Altman 1986 ) Global functional status I , II III accord ACR classification ( see Appendix 5 ) . Patient minimum 40mm 100mm VAS ( WOMAC pain subscale ) baseline / randomisation . In addition , baseline pain must stable least 72 hour prior randomisation base patient 's assessment . Patient maximum 80mm 100mm VAS ( WOMAC pain subscale ) screening . Intolerance paracetamol . Any clinical biological abnormality find screening ( related disease investigation ) , opinion investigator , clinically significant would preclude safe participation study ( e.g . current malignancy , human immunodeficiency virus ( HIV ) infection , significant mental illness ) . QTc ≥450msecs base 12lead ECG obtain brief recording period . This apply QTc interval measure either Bazzett 's Fridericia 's formula ( machine manual overread , male female subject ) . Subjects one creatinine , bilirubin , alanine aminotransferase ( ALT ) aspartate aminotransfarase ( AST ) &gt; 1.5 time upper limit normal ( ULN ) screen exclude . Subjects two bilirubin , ALT AST ULN exclude . Chronic Hepatitis B C , evidence positive Hepatitis B surface antigen ( HbsAg ) Hepatitis C antibody History chronic alcoholic liver disease Impaired renal function ( estimate GFR &lt; 30mL/min ) Use potent CYP3A4 inhibitor ( e.g . amiodarone , cyclosporine , diltiazem , elfinavir , indinavir , ritonavir , cimetidine , clarithromycin , erythromycin , fluconazole , itraconazole , ketoconazole , miconazole , nefazodone , verapamil ) Use methotrexate . Use anticoagulant ( warfarin , heparin ) antiplatelet aggregation agent ( exclude lowdose aspirin ) condition associate decreased haemostasis Abuse alcohol define average weekly intake great 21 unit average daily intake great 3 unit ( male ) define average weekly intake great 14 unit average daily intake great 2 unit ( female ) . 1 unit equivalent halfpint ( 220mL ) beer 1 ( 25ml ) measure spirit 1 glass ( 125ml ) wine . A history clinically significant drug alcohol abuse , define Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) criteria [ Hochberg , 1991 ] Participation another investigational drug device study 3 month prior Baseline/Randomisation Visit Inability unwillingness comply study restriction An unwillingness male subject use condom/spermicide , addition female partner use another form contraception , IUD , diaphragm spermicide , oral contraceptive , injectable progesterone , subdermal implant tubal ligation , engage sexual intercourse female partner could become pregnant . This criterion must follow time first dose study medication three month last dose study medication . Exclusion criterion related OA : Secondary cause arthritis knee include septic arthritis , inflammatory joint disease , articular fracture , major dysplasia congenital abnormality , ochronosis , acromegaly , hemochromatosis , Wilson 's disease , primary osteochondromatosis Had low extremity surgery ( include arthroscopy ) within 6 month prior screen schedule surgery kind study period Significant prior injury index knee within 12 month prior screen Use low extremity assistive device cane knee brace ( use 'shoe lift ' permit ) Disease spine low extremity joint sufficient degree affect index knee Any musculoskeletal arthritic condition may affect interpretation clinical efficacy and/or safety data otherwise contraindicate participation clinical study ( i.e. , currently symptomatic fracture concurrent rheumatic disease limit fibromyalgia , rheumatoid arthritis , Reiter 's syndrome exclude ) Use analgesic , COX2 inhibitor NSAID [ include topical NSAIDs ; exclude lowdose aspirin ( ≤325mg per day ) ] , protocol define rescue therapy ( paracetamol ) , within 5× halflife ( hour ) prior first dose day study Corticosteroid use prior baseline follow : Intraarticular injection steroid index knee within previous 3 month Intraarticular steroid injection site index knee within Intramuscular corticosteroid injection within previous 3 month Oral corticosteroid within previous 1 month Received hyaluronan injection index knee within previous six month prior baseline Initiation change establish physiotherapy program within 2 week prior baseline study period . An established physiotherapy program may continue throughout study period unchanged frequency intensity Recent start change dose regimen ( ≤3 month prior baseline ) OA‑specific therapy ( i.e. , nutraceutical product ) include limited chondroitin keratin sulfate , sadenosyl methionine ( SAMe ) glucosamine preparation</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>osteoarthritis pain assessment</keyword>
</DOC>